Atea Pharmaceuticals Inc AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports results on March 6 for the period ending December 31 2024
LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 37 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.20, above its last closing price of $2.90.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.46 | -0.49 | -0.37 | Beat | 25.3 |
Jun. 30 2024 | -0.76 | -0.76 | -0.48 | Beat | 37.3 |
Mar. 31 2024 | -0.63 | -0.61 | -0.75 | Missed | -23.6 |
Dec. 31 2023 | -0.49 | -0.50 | -0.47 | Beat | 5.4 |
Sep. 30 2023 | -0.45 | -0.48 | -0.40 | Beat | 16.1 |
Jun. 30 2023 | -0.45 | -0.47 | -0.34 | Beat | 27.7 |
Mar. 31 2023 | -0.47 | -0.48 | -0.43 | Beat | 9.9 |
Dec. 31 2022 | -0.44 | -0.45 | -0.41 | Beat | 8.9 |
This summary was machine generated March 4 at 21:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。